ILK and chronic myelogenous leukemia, BCR-ABL1 positive: The quiescent aspect has been investigated in chronic myeloid leukemia (CML) where the integrin-linked kinase (ILK) was pointed out as a survivor mediator critical to tyrosine kinase inhibitors and quiescent stem cells [156].